Research Progress of Immunogenic Cell Death in the Treatment of Lung Cancer
10.3870/j.issn.1672-0741.24.01.001
- VernacularTitle:免疫原性细胞死亡在肺癌治疗中的研究进展
- Author:
Jianlun LI
1
;
Sijian HUANG
;
Man MOU
Author Information
1. 武汉科技大学医学院感染免疫与肿瘤微环境研究所,职业危害识别与控制湖北省重点实验室,武汉 430065
- Keywords:
lung cancer;
immunogenic cell death;
damage-associated molecular pattern;
ICD inducer
- From:
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
2024;53(4):552-557
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer,a malignant tumor with high incidence and mortality rate,is characterized by multiple types,high malignancy and poor prognosis.Immunotherapy is to stimulate and enhance immune system of the host to achieve the purpose of controlling and killing tumor cells,and has been proven to have good therapeutic effects on many types of cancer.Immunogenic cell death(ICD)is a programmed cell death characterized by the release of large amounts of damage-associated molecular pat-terns(DAMPs).After treatment of certain chemotherapy drugs,physical therapy,biological therapy or combination therapy,lung cancer cells will undergo ICD,altering from non-immunogenic to immunogenic.Immune cells will then be recruited and ac-tivated,and finally activate and enhance anti-tumor immune response in the body.This article reviews the mechanism of ICD and the application of ICD inducers in the treatment of lung cancer.
